RSG
77
4
NOV
58
-2
SIG
47
-2
COF
63
-4
TXN
49
-6
ACN
70
5
LRCX
46
-2
SE
60
-5
DE
36
-2
WHR
70
4
LEG
31
3
MPC
47
3
QCOM
55
-2
XRX
34
-3
HSY
43
3
GS
75
-4
CMG
69
-3
BK
72
-2
NTAP
61
-3
HES
66
3
RSG
77
4
NOV
58
-2
SIG
47
-2
COF
63
-4
TXN
49
-6
ACN
70
5
LRCX
46
-2
SE
60
-5
DE
36
-2
WHR
70
4
LEG
31
3
MPC
47
3
QCOM
55
-2
XRX
34
-3
HSY
43
3
GS
75
-4
CMG
69
-3
BK
72
-2
NTAP
61
-3
HES
66
3
Financhill
Back

Cara Therapeutics Quote, Financials, Valuation and Earnings

Trump wins! Dow to 75,000? Details here

See the explosive "Document 20" details here.
Sell
50

CARA
Cara Therapeutics

Last Price:
0.33
Seasonality Move:
3.84%

7 Day Trial

ALL ACCESS PASS

$ 7

"This Changes Everything" - Trump Hands Millions Massive IRS Gift

Learn More Here

Cara Therapeutics Price Quote

$0.33
+0.00 (+0.64%)
(Updated: November 14, 2024 at 5:55 PM ET)

Cara Therapeutics Key Stats

Sell
50
Cara Therapeutics (CARA) is a Sell
Day range:
$0.32 - $0.34
52-week range:
$0.24 - $1.31
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.69
P/B ratio:
1.61%
Volume:
639.3K
Avg. volume:
630.4K
1-year change:
-72.21%
Market cap:
$18.7M
Revenue:
$21M
EPS:
$-2.04

How Much Does Cara Therapeutics Make?

Is Cara Therapeutics Growing As A Company?

  • What Is Cara Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.86%
  • What Is Cara Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Cara Therapeutics Stock Price Performance

What Is Cara Therapeutics 52-Week High & Low?

Cara Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Cara Therapeutics?

  • How Much Debt Does Cara Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Cara Therapeutics Have?
    Cash and short term investments quarterly total is $56.6M
  • What Is Cara Therapeutics’s Book Value Per Share?
    Book value per share is 0.21

Is Cara Therapeutics Cash Flow Positive?

  • What Is CARA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$79.9M
  • What Is Cara Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $36.3M
  • What Is Cara Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $34.2M

Cara Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    CARA return on invested capital is -189.52%
  • What Is Cara Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -103.2%
  • What Is CARA Return On Equity?
    ROE is a measure of profitability and is -189.52%

Cara Therapeutics Earnings Date & Stock Price

Cara Therapeutics Competitors

  • Who Are Cara Therapeutics's Competitors?
    Below is a list of companies who compete with Cara Therapeutics or are related in some way:
    • Perspective Therapeutics Inc (CATX)
    • Cocrystal Pharma Inc (COCP)
    • Citius Pharmaceuticals Inc (CTXR)
    • Oragenics Inc (OGEN)
    • Alaunos Therapeutics Inc (TCRT)

Cara Therapeutics Dividend Yield

Cara Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -33%
Revenue: -85.71% -15.56%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 4
Sell Recommendations: 0
Price Target: 1.66
Upside from Last Price: 404.73%

Major Shareholders

  • How many CARA shares are owned by institutional investors?
    29.1M CARA shares are owned by institutional investors
  • How many CARA shares are owned by insiders?
    3.1M CARA shares are owned by insiders